U.S. Biodefense Industry Research 2024-2030: Focus on Anthrax, Small Pox, Botulism, & Radiation/Nuclear


Dublin, July 24, 2024 (GLOBE NEWSWIRE) -- The "U.S. Biodefense Market Size, Share & Trends Analysis Report by Product (Anthrax, Small Pox, Botulism, Radiation/nuclear), and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.

The U.S. biodefense market is anticipated to reach USD 17.90 billion by 2030, and is expected to grow at a CAGR of 4.1% from 2024 to 2030

The U.S. biodefense market is driven by factors such as increased government funding, global health concerns, technological advancements, regulatory requirements, the need for collaboration and preparedness, and economic incentives. These drivers contribute to the growth and development of the industry, ensuring that effective biodefense solutions are available to protect populations from potential biological threats.

The U.S. biodefense market benefits from rapid advancements in technology, such as genomics, bioinformatics, and synthetic biology. These innovations enable faster identification of pathogens, development of targeted therapies, and improved diagnostics.



In September 2022, the Department of Defense (DoD) planned to invest USD 1 billion to boost domestic bio-industrial manufacturing infrastructure, facilitating accessibility for U.S. innovators, which aimed at incentivizing private and public sectors to expand manufacturing capacities, particularly for critical chemicals vital to commercial and defense supply chains. In addition, the DoD was expected to allocate an extra USD 200 million to enhance biosecurity and cybersecurity measures for these facilities.

Collectively, the U.S. Department of Agriculture (USDA) was expected to introduce a USD 500 million grant program in summer 2022 to foster independent, innovative, and sustainable American fertilizer production, leveraging advancements in biotechnology and biomanufacturing to support domestic farmers.

U.S. Biodefense Market Report Highlights

  • Anthrax dominated the product segment with 28.1% share in 2023 owing to its high lethality, ease of production, stability, potential for mass casualties, and the ongoing need to improve existing treatments and vaccines.
  • The radiation/nuclear segment is expected to grow at a significant CAGR over the forecast period.
  • The increasing incidents of bioterrorism, the potential for new and emerging infectious diseases are contributing to the growth of the U.S. biodefense market.
  • In January 2022, Integrated Viral Protection LLC (IVP) launched a portable air filtration device capable of eliminating a wide range of airborne viruses, including COVID-19 and anthrax spores, in a single pass, boasting exceptional efficacy with patented biodefense technology.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

Companies Featured

  • XOMA Corporation
  • Altimmune, Inc.
  • EMERGENT
  • Dynavax Technologies
  • SIGA Technologies
  • Elusys Therapeutics, Inc.
  • Ichor Medical Systems
  • Dynport Vaccine Company (General Dynamics Information Technology, Inc.)
  • Cleveland Biolabs
  • Bavarian Nordic
  • Ology Bioservices, Inc.
  • Alnylam Pharmaceuticals, Inc.

Key Attributes:

Report AttributeDetails
No. of Pages80
Forecast Period2023 - 2030
Estimated Market Value (USD) in 2023$13.4 Billion
Forecasted Market Value (USD) by 2030$17.9 Billion
Compound Annual Growth Rate4.1%
Regions CoveredUnited States



Key Topics Covered:

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.5. Information or Data Analysis
1.6. Market Formulation & Validation
1.7. Model Details

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.3. Competitive Insights

Chapter 3. U.S. Biodefense Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. U.S. Biodefense Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.2. PESTEL Analysis

Chapter 4. U.S. Biodefense Market: Product Estimates & Trend Analysis
4.1. Product Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Biodefense Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.4.1. Anthrax
4.4.2. Smallpox
4.4.3. Botulism
4.4.4. Radiation/nuclear
4.4.5. Others

Chapter 5. Competitive Landscape
5.1. Recent Developments & Impact Analysis, By Key Market Participants
5.2. Company/Competition Categorization
5.3. Vendor Landscape
5.3.1. List of key distributors and channel partners
5.3.2. Key customers
5.3.3. Key company heat map analysis, 2023
5.4. Company Profiles
5.4.1. Company overview
5.4.2. Financial performance
5.4.3. Product benchmarking
5.4.4. Strategic initiatives

For more information about this report visit https://www.researchandmarkets.com/r/jkm6w2

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

 
U.S. Biodefense Market

Coordonnées